Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226232 · ClinicalTrials.gov registry record · Phase 3
Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
A Phase 3 study, sponsored by VA Office of Research and Development.
- Not yet
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
NCT07226232: Clinical Trial Phase 3 study, sponsored by VA Office of Research and Development.
NCT07226232 is a Phase 3 study that has not yet begun recruiting, run by VA Office of Research and Development. The registered enrollment target is 240 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07226232, a Phase 3 study, has not yet begun recruiting, sponsored by VA Office of Research and Development.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
Study Summary
The purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S. military Veterans with and without (±) concurrent posttraumatic stress disorder.
Interventions
- DRUG Psilocybin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2026-07-30 |
| Est. Completion | 2031-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07226232
The ClinicalTrials.gov registry entry for NCT07226232 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Psilocybin is the first listed.
NCT07226232 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07226232 about?
NCT07226232 is a clinical study titled "Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression". The purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S. military Veterans with and without (±) concurrent posttraumatic stress disorder.
What is the current status of trial NCT07226232?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2026-07-30. Estimated completion is 2031-06-30.
What interventions are being tested in trial NCT07226232?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT07226232?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.